Načítá se...
Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn’s disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit...
Uloženo v:
| Vydáno v: | Clin Exp Gastroenterol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5697448/ https://ncbi.nlm.nih.gov/pubmed/29180886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEG.S110546 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|